SEC Form 4 · accession 0001209191-15-001587
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Craig Fraser
Officer — Chief Operating Officer
Period of report
Dec 31, 2014
Accepted (ET)
Jan 5, 2015 · 7:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $15.95 | Dec 31, 2014 | A | 45,000 | A | — | Jan 23, 2022 | Common Stock | 45,000 | 45,000 | D |
Explanation of responses
- F1On January 23, 2012, the reporting person was granted an option to purchase 45,000 shares of common stock, subject to time and performance vesting criteria. The time and performance criteria have been met with respect to this award.